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ABSTRACT
Introduction: Human onchocerciasis caused by the filarial nematode parasite Onchocerca volvulus 
remains a major cause of debilitating disease infecting millions primarily in Sub-Saharan Africa. The 
development of a prophylactic vaccine, along with mass drug administration, would facilitate meeting 
the goal of onchocerciasis elimination by 2030.
Areas covered: Models used to study immunity to Onchocerca include natural infection of cattle with 
Onchocerca ochengi and O. volvulus infective third-stage larvae implanted within diffusion chambers in 
mice. A vaccine, comprised of two adjuvanted recombinant antigens, induced protective immunity in 
genetically diverse mice suggesting that it will function similarly in diverse human populations. These 
antigens were recognized by immune humans and also induced protective immunity against Brugia 
malayi. We describe the development of a fusion protein composed of the two vaccine antigens with 
the plan to test the vaccine in cows and non-human primates as a prelude to the initiation of phase 1 
clinical trials.
Expert opinion: The adjuvanted O. volvulus vaccine composed of two antigens Ov-103 and Ov-RAL-2 
was shown to be consistently effective at inducing protective immunity using multiple immune 
mechanisms. The vaccine is ready for further evaluation in other animal models before moving to 
clinical trials in humans.
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1. Onchocerciasis – the need for a prophylactic 
vaccine
Human onchocerciasis (‘river blindness’), caused by the filarial 
nematode parasite Onchocerca volvulus, is a major cause of 
infectious blindness, skin disease, and chronic disability. It 
infects many millions worldwide with 99% of the cases sus-
tained in 31 countries of Sub-Saharan Africa- resulting in wide-
spread vision impairment and blindness. Current estimates put 
120 million people at risk [1,2]. The Global Burden of Disease 
Study estimated in 2017 that there were 20.9 million people 
infected worldwide, of which 14.6 million had skin disease and 
1.15 million had vision loss [3,4] (Figure 1). Importantly, it has 
become apparent in recent years that onchocerciasis- 
associated epilepsy (OAE) is also an important public health 
problem caused by onchocerciasis. In a recent door-to-door 
survey in Mvolo, an onchocerciasis endemic region in South 
Sudan, the prevalence of epilepsy in this population was 
higher (5.1%) than blindness (2.8%) [5].
Long the focus of efforts to alleviate morbidity and lost 
productivity, onchocerciasis has been identified by the World 
Health Organization as a potential candidate for global elim-
ination through mass drug administration (MDA) of the 
donated drug ivermectin (IVM) (Mectizan®) [6–8]. This plan 
began in the 1990’s as the ‘Onchocerciasis Elimination in the 
Americas’ and later by the ‘African Programme for 
Onchocerciasis Control’ (APOC) in 1995 with a World Health 
Assembly goal to establish community-based sustainable 
treatments of 50 million people in 19 African countries having 
meso- and hyper-endemicity by 2010 [7,9]. In 2015, the mis-
sion of onchocerciasis elimination for Africa was passed from 
APOC to its successor, the Expanded Special Programme for 
the Elimination of Neglected Tropical Diseases [10]. Addition 
of vegetation ‘slash and clear’ for vector control, as 
a supplement to MDA, has been proposed as an adjunct to 
accelerate elimination of onchocerciasis [11]. However, numer-
ous and formidable technical and logistical obstacles must still 
be overcome before the ambitious goal of elimination by 2030 
can be achieved in Africa [9,12]. These include (1) MDA of IVM 
cannot be used in 11 Central African countries co-endemic 
with Loa loa infections due to the risk of severe adverse events 
[13–16]; (2) The few drugs active against the adult stage of the 
parasite are not used for MDA, and IVM, as well as the recently 
approved drug moxidectin, are only effective against micro-
filariae [17]; (3) The practical complication of treating people 
for 14 to 35 years compounds the difficulty of implementing 
the plan [7,8]; (4) Experimental studies indicate that suscept-
ibility to reinfection may increase after treatment, further 
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complicating the disruption of the transmission cycle [18–20]; 
and finally (5) The potential emergence of IVM-resistant 
O. volvulus, may limit the long-term effectiveness of MDA 
and, in time, undermine all of the gains achieved by oncho-
cerciasis control programs [21–29]. Originally developed for 
veterinary use, IVM was re-purposed for use as 
a microfilaricidal drug in humans, initially to great effect 
[30,31]. While current evidence for IVM resistance in 
O. volvulus is far from definitive, it is quite clear that sub- 
optimal responses to IVM in the treatment of river blindness 
have been identified, in particular, as manifested by faster 
rates of microfilarial skin repopulation linked to decreased 
effects of IVM on female worm fecundity [32]. It should be 
noted that IVM was first used for many years to prevent 
heartworm disease caused by the filarial parasite Dirofilaria 
immitis in domestic dogs and cats, but it has been demon-
strated that IVM-resistant D. immitis is already circulating in 
the United States [33]. Complicating the challenges with rely-
ing only on MDA with IVM is that IVM is not administered to 
children under 5 years old and a macrofilaricidal drug, dox-
ycycline, cannot be given to children under 9 thus limiting the 
indications for these two drugs. In addition, doxycycline 
requires 6 weeks of treatment to be effective which further 
diminishes its utility [34]. Thus, children are not only vulner-
able to infection but become reservoirs for transmission [35].
The successes of the control programs must be weighed 
against the fact that since 1995 only a 31% reduction in the 
incidence of onchocerciasis has been achieved in Africa [2,36– 
38]. In 2016, APOC called for 1.15 billion treatments until 2045, 
though many neglected tropical disease experts doubt that 
onchocerciasis can ever be eliminated through MDA with IVM 
alone, due to the aforementioned limitations [39,40]. 
Moreover, due to the high cost, MDA is not currently imple-
mented in areas of low prevalence in Africa. This may con-
tribute to continued transmission through human migrations 
that may result in reintroducing the parasite back into regions 
where it had once been controlled [16].
It is clear to the public health community dedicated to the 
control of this disease that additional tools are critically 
needed to support the existing control measures [41–43]. It 
is equally clear that an effective vaccine aimed at preventing 
infection with O. volvulus infective larvae (L3) would be an 
essential, additional component in the effort to control onch-
ocerciasis. Moreover, it is recognized that a high burden of 
OAE in onchocerciasis endemic areas with high ongoing trans-
mission adds to the importance of preventing new infections 
by a vaccine targeting children under 5 years old who are at 
risk for developing OAE including nodding syndrome [44]. 
Vaccine development against infection with O. volvulus has 
been the subject of much thought and work in the past 
through the funding (1985–1999) from the Edna McConnell 
Clark Foundation [45–49]. This approach was endorsed by 
APOC that strongly encouraged the development of 
a prophylactic vaccine as part of new tools needed to meet 
the onchocerciasis elimination agenda [49,50]. This was further 
restated in a recent report listing the new global targets for 
NTDs in the WHO roadmap 2021–2030 [51]. In 2015, an inter-
national consortium launched a new global initiative, known 
as TOVA – The Onchocerciasis Vaccine for Africa [52]. TOVA is 
primarily focused on a vaccine comprised of recombinant 
protein(s) and various adjuvants as described below, with 
the goal of developing a vaccine that meets the desired target 
product profiles [53]. It is envisioned that the preventive 
Onchocerca vaccine will be used to partially protect vulnerable 
populations, children under 5 years of age who have not yet 
had access to MDA with IVM, against infection with L3. 
Consequently, the adult worm burden and the number of 
microfilariae produced by adult female worms will be reduced, 
resulting in reduced pathology and rates of transmission. 
Based on mathematical modeling, with the assumption that 
such a vaccine has an initial prophylactic efficacy of 50% and 
a therapeutic efficacy of 90% against microfilariae, the vaccine 
would have a beneficial impact in onchocerciasis–loiasis co- 
endemic areas by markedly reducing microfilarial loads in the 
Article highlights
● A vaccine composed of two antigens Ov-103 and Ov-RAL-2 in com-
bination with the adjuvants alum or Advax-2 was shown to consis-
tently induce protective immunity to O. volvulus in mice.
● The vaccine was effective at inducing protective immunity in geneti-
cally diverse mice and against other filarial worms.
● Trials are ongoing testing the vaccine against natural infection of 
cows with O. ochengi
● A fusion protein comprised of the two antigens is undergoing testing 
in mice, cows and non-human primates prior to clinical trials
Figure 1. Stages of Onchocerca volvulus and clinical presentation.
(a) Infective third-stage larvae (L3s) recovered from infected black flies (Photo credit: Sara. Lustigman, New York Blood Center). (b) O.volvulus female worm released from nodule by 
collagenase digestion (Photo credit: Adrian JF Luty, French National Research Institute for Sustainable Development). (c) Subcutaneous fibrotic Nodule found on a child from Ghana 
containing adult O. volvulus. (Photo credit: Peter Soboslay, PLOS Neglected Tropical Diseases: Of Mice, Cattle, and Humans: The Immunology and Treatment of River Blindness). 
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young (under 20 years) age groups, which are a major reser-
voir for transmission [35]. Thus, an anti-larval vaccine would 
support further reduction in transmission and as a result 
ensure the success of the existing MDA with IVM. At the 
same time, vaccination would allow for diminished subse-
quent use of drugs and forestall drug resistance.
2. Foundation Studies – immunity in humans to 
O. volvulus and the development of animal models 
for the study of protective immunity
The feasibility of an anti-O. volvulus larvae vaccine is sup-
ported by uncovering two distinctive expressions of anti-L3 
protective immunity within the O. volvulus endemic popula-
tion: (1) Immunity that impedes the development of patent 
infections (microfilaria positive) in the putatively immune (PI) 
individuals (i.e. individuals that had no clinical manifestations 
of the disease, even though they lived for at least 10 years 
within regions where onchocerciasis is endemic and were 
exposed to high transmission rates of infection) [54–57]; (2) 
Concomitant immunity to O. volvulus L3, which develops in 
the patently infected (INF) individuals with increasing age and 
is independent of the immune responses that are induced by 
the adult worms and microfilariae associated with patent 
infection. Concomitant immunity prevents most of the newly 
acquired L3 infections from developing and results in a stable 
adult worm burden in the INF [18,58,59]. This immunity is not 
directed against the adult or the microfilaria stages of the 
parasite. Some of the mechanisms of acquired protective 
immunity against O. volvulus infection in humans (reviewed 
in [45,60,61]) were shown to be associated with their ability to 
mount mixed Th1/Th2 responses against O. volvulus L3 and/or 
molting L3 [57,59], as well as the presence of cytophilic anti-
bodies that together with the cytokines produced, induce 
efficient anti-L3 antibody-dependent cell mediated cytotoxi-
city (ADCC) reactions against L3 [59,62–70].
Research on the biology, pathology and immunology of 
O. volvulus has been limited by the host range of the infection, 
consisting of only naturally infected humans and gorillas, 
although chimpanzees and mangabey monkeys are partially 
permissive to patency in laboratory settings [71,72]. The mean 
pre-patent period in primates ranges from 12 to 23 months 
that adds to the limitations of the primate hosts for use in 
experimental studies [71]. In addition, after skin penetration, 
the L3 of O. volvulus migrates throughout the tissues making 
accurate recovery of the parasites from infected animals chal-
lenging. To overcome these impediments, a system was devel-
oped in which L3 were implanted subcutaneously within 
diffusion chambers, which were designed to contain larvae 
in vivo without restricting the infiltration of host cells into 
the parasite microenvironment. This system allows recovery 
of early larval stages and the analysis of the local innate and 
adaptive immune responses to the infections. Diffusion cham-
bers containing L3 were implanted in primates including 
chimpanzees, mangabey monkeys, rhesus monkeys, and squir-
rel monkeys as well as rodents – including 4 inbred strains of 
rats, 6 inbred strains of mice, and gerbils. The L3 developed 
into fourth-stage larvae (L4) and increased in length over the 
63 days in vivo in all tested hosts except for larvae implanted 
in squirrel monkeys and in rats. Importantly, equal survival 
rates were observed with fresh and cryopreserved larvae 
[73]. The combination of mouse susceptibility, development 
of L3 into L4, efficient recovery of parasites and the use of 
cryopreserved larvae opened the door for the use of this 
model to identify protective vaccine candidates and to 
develop a prophylactic vaccine against the early stages of 
the infection. Importantly, the protective immunity that devel-
ops in humans shares many characteristics with those 
described in the mouse vaccine model, as discussed 
below [74].
As an alternative approach to studying O. volvulus, other 
species of Onchocerca have been identified but, unlike 
O. volvulus, most of these parasitize ungulates including 
domestic cattle [75]. While most of these are of negligible 
importance for animal health, they present a unique opportu-
nity as model systems for studying human onchocerciasis, 
enabling the study of natural infection and transmission as 
well as protective immunity in a way that cannot otherwise be 
achieved outside human clinical trials.
Onchocerca ochengi is the most notable of these, sharing 
many key characteristics with O. volvulus in terms of its gen-
ome, biology, lifecycle and transmission including its arthro-
pod vector (Simulium damnosum s.l.), the sedentary nodule- 
forming nature of adult females, microfilaridermia and pre-
sence of the endosymbiont Wolbachia [76–78]. Indeed, these 
two parasites are so similar it is hypothesized that O. volvulus 
evolved either directly from O. ochengi or another common 
cattle-infecting ancestor, jumping hosts in a speciation event 
coinciding with the recent introduction (in an evolutionary 
context) of domestic cattle to the African continent [79]. This 
theory is supported by numerous phylogenetic studies show-
ing the close relationship of these two sister species [80,81]. 
Importantly in the context of vaccine development, this rela-
tionship also extends to antigenic homology [82,83]. 
Accordingly, a zooprophylactic effect against infection with 
O. volvulus has been inferred epidemiologically in humans 
that results from natural exposure to O. ochengi in co- 
endemic regions [84].
The bovine-O. ochengi natural transmission model is there-
fore a valuable tool for human onchocerciasis research allowing 
the evaluation and quantification of key aspects of infection and 
the lifecycle, including disease kinetics, adult worm and micro-
filarial burdens, female worm fecundity and viability. It has been 
also used extensively to aid investigations into basic parasite 
biology, including host-parasite interactions, vector biology and 
epidemiology as well as more applied clinical studies focused on 
testing vaccine candidates and efficacy trials of micro- and 
macrofilaricidal drugs [85–95] (Figure 2).
3. Can animals be immunized against infection with 
Onchocerca spp and develop adaptive protective 
immunity?
3.1. O. ochengi bovine model
Naturally acquired immunity to O. ochengi has been demon-
strated in cattle to be related to a number of factors including 
host heterogeneity. A small proportion of animals in endemic 
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regions demonstrate a putative immunity (similar to observa-
tions from human populations). Female cattle and older ani-
mals demonstrate an increased level of immunological 
protection against microfilaridermia compared to male and 
younger animals, respectively [87,89,96].
Attempts to induce immunity through experimental immu-
nizations have also yielded positive results. Cattle immunized 
with irradiated O. ochengi L3 demonstrated an 84% reduction in 
adult female worm burdens following experimental challenge 
and 53% reduction in microfilarial burdens following natural 
challenge compared to unvaccinated control animals [89]. 
Similarly, following an initial experimental ‘immunization’ with 
live O. volvulus L3, cattle demonstrated an 86% reduction in 
O. ochengi adult female worm burdens compared to control 
animals following subsequent experimental challenge with L3 
[97]. In 2009, a study evaluating the co-administration of eight 
recombinant O. volvulus antigen candidates, each formulated in 
Freund’s or alum adjuvants, had shown that although no sig-
nificant difference in adult female worm burdens between vac-
cinated and unvaccinated animals following subsequent 
exposure to natural infections was found, there was 
a significant reduction in the frequency of microfilaridermia 
present in vaccinated versus unvaccinated control animals [95]. 
This reduction was associated with antigen-specific serum IgG1 
(Th2-associated antibody) and IgG2 (Th1-associated antibody) 
responses [98]. The presence of IgG2 isotype antibody is of 
particular interest in vaccinated protected cattle, as this isotype 
is commonly associated with Th1-type immune responses and 
ADCC activity in cattle [99]. The outcome of this vaccine study is 
highly important because only the microfilarial stage is respon-
sible for transmission and disease symptoms in onchocerciasis. 
Therefore, even if a vaccine is only effective against microfilariae, 
it could still play a key role in elimination programs by reducing 
transmission potential [35].
3.2. O. volvulus mouse model
The mouse diffusion chamber model was validated in multiple 
studies as a valuable tool for the development of a vaccine 
against O. volvulus. Initially, it was determined that protective 
immunity directed at larvae within diffusion chambers could 
develop in mice following vaccination. Statistically significant 
levels of protective immunity were induced in BALB/cByJ mice 
following immunization with irradiated L3 [100]. Protective 
immunity induced by irradiated L3 was dependent on IL-4- 
and IL-5, and independent of IFN-γ, suggesting that protective 
immunity was based on a Th2 CD4+ T cell response [101,102]. 
This conclusion was confirmed by studies that demonstrated 
that the mechanism of protective immunity induced by irra-
diated L3 required IgE and eosinophils [103,104].
4. Identification and selection of the recombinant 
O. volvulus vaccine antigens
Although irradiated L3 were shown to consistently induce sig-
nificant levels of protective immunity to O. ochengi in cows and 
to O. volvulus in mice, it was clear that use of L3 recovered from 
infected black flies would never be a realistic source of antigen 
for a vaccine to be used in human populations. To overcome this 
obstacle, two basic strategies were used to identify and clone 
O. volvulus target vaccine antigens [53]. The first exploited the 
potential involvement of antibodies in protective immunity by 
immunoscreening various O. volvulus cDNA libraries to identify 
target proteins. The second strategy identified and isolated 
molecules thought to be essential during the infection process. 
Twelve of 26 recombinant antigens identified by the first strategy 
and four of 18 identified by the second strategy were confirmed 
to induce partial but statistically significant protection in the 
presence of an adjuvant (alum, block copolymer, or Freund’s 
complete adjuvant) or using a DNA immunization when tested 
in the O. volvulus mouse model [61]. Each of these antigens was 
produced and tested under unique conditions. The next step in 
the development of the O. volvulus vaccine was to produce 
antigens in one laboratory under standardized conditions so 
that the antigens could be compared to each other for vaccine 
efficacy. From the list of protective antigens, eight were selected 
using stringent scoring criteria and then produced in two differ-
ent expression systems, Escherichia coli and Pichia pastoris. All of 
the immunizations were with alum as the adjuvant to favor a Th2 
response. The recombinant antigens Ov-103 produced by E. coli 
and Ov-RAL-2 produced by P. pastoris emerged as lead vaccine 
candidate antigens [105]. Both proteins are localized on the 
Figure 2. The bovine-Onchocerca ochengi natural transmission model offers a number of opportunities for the study vaccines against human onchocerciasis.
(a.) Natural exposure to infection and quantification of the level of challenge through bait-capture of Simulium damnosum s.l. (circled), (b.) Longitudinal observation of infection kinetics 
including emergence of adult female nodules in situ (arrow) and associated clinical parameters, (c.) Quantification of microfilarial burdens through skin snips, and (d.) Assessment of adult 
worm biometrics including size, viability and fecundity via nodulectomies (Photo credits: John Graham-Brown, University of Liverpool). 
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surface and glandular esophagus of L3 as well as in the hypo-
dermis and cuticle of adult worms and on the surface of micro-
filariae [106]. As the protective immunity induced by the two 
antigens was partial, it was hypothesized that immunizing mice 
with both antigens would enhance the protective immune 
response. Mice were immunized with either a fusion or co- 
administration of the two antigens. IgG antibody titers were 
higher with the combined antigens than with individual antigens 
demonstrating that they were not immunologically competitive. 
This is in contrast to other combined O. volvulus vaccine antigens 
that were found to compete with each other, resulting in 
reduced antibody titers [107]. However, the levels of protective 
immunity induced by the co-administered vaccines were not 
enhanced as compared to protection in mice immunized with 
the individual antigens. Importantly vaccinated mice did not 
develop IgE responses to either of the antigens [105]. To deter-
mine the role of antibody in the protective immune response, 
AID-/- mice, which do not produce IgG, were immunized with 
either Ov-103 or Ov-RAL-2 formulated with alum. In the absence 
of parasite-specific IgG immunized AID-/-mice did not develop 
protective immunity. Furthermore, significant levels of parasite 
killing in Ov-103 and Ov-RAL-2 vaccinated mice only occurred 
when cells entered the parasite microenvironment. Based on 
these studies, it was concluded that protective immunity 
induced by Ov-103 and Ov-RAL-2 was dependent on crosstalk 
between IgG and immune cells which suggests an ADCC- 
dependent mechanism [108].
It was next hypothesized that the efficacy of an Onchocerca 
vaccine could be amplified if the type of immune responses 
induced by the vaccine were expanded. To test this hypothesis, 
mice were immunized with Ov-103 and Ov-RAL-2 independently 
or co-administered in combination with five different adjuvants 
known to induce Th1, Th2 or combined Th1/Th2 responses. The 
highest levels of larval killing were achieved in mice immunized 
with the two antigens each formulated with delta inulin and CpG 
oligodendronucleotide (ODN)-based adjuvant AdvaxTM-2 
(Advax-2) as the adjuvant [109]. This vaccine induced significant 
Th2- associated IgG1 and Th1-associated IgG2a/b antibody 
responses as well as combined Th2 cytokines and IFN-γ in recall 
responses, indicating the induction of a mixed Th1/Th2 response. 
Both IgG1 and IgG2 mouse antibodies are cytophilic and could 
participate in ADCC [98]. Immunization with the co-administered 
vaccines increased antibody endpoint titers, yet correlation ana-
lyses comparing parasite recovery numbers and endpoint titers 
did not reveal consistent significant levels of statistical correla-
tion. Importantly, the two antigens appeared to act collabora-
tively, boosting the antibody response to the reciprocal antigen 
and suggested that Ov-103 and Ov-RAL-2 induce two unique but 
synergistic protective killing mechanisms [110].
5. Validating the Ov-103 and Ov-RAL-2 Onchocerca 
vaccine for advanced preclinical development
5.1. Responses in humans to the Ov-103 and Ov-RAL-2 
vaccine antigens
As Ov-103 and Ov-RAL-2 were identified as effective vaccine 
antigens in mice, it was important to verify that they were also 
associated with protective immunity in humans. Elevated IgG1 
and IgG3 responses to Ov-103 and Ov-RAL-2 were seen in 86% 
of putatively immune individuals and 95% of individuals who 
have developed concomitant immunity with age. Moreover, 
human monospecific anti-Ov-103 antibodies but not anti-Ov- 
RAL-2 antibodies significantly inhibited the molting of L3 
in vitro by 46% in the presence of naïve human neutrophils, 
while both monospecific anti-Ov-103 and anti-Ov-RAL-2 anti-
bodies significantly inhibited the molting by 70–80% when 
cultured in the presence of naive human monocytes. 
Interestingly, inhibition of molting by Ov-103 antibodies and 
monocytes was only partially dependent on contact with the 
cells, while inhibition of molting with Ov-RAL-2 antibodies was 
completely dependent on contact with the monocytes. These 
observations further suggest that the two antigens induce 
different mechanisms of protective immunity in humans [108].
The onchocerciasis vaccine is aimed at preventing the 
establishment of infection in children under 5 years old [52]. 
Accordingly, anti-Ov-103 and Ov-RAL-2 IgE responses were 
tested in 73 children of 1–5 years of age vs. 27 children aged 
6–8 from a highly endemic region in Ghana. Two tests were 
used, ELISA and an antigen-specific IgE ImmunoCap assay that 
determines whether the antigen-specific IgE antibodies can 
mediate functional responses using a basophil histamine 
release assay [111,112]. None of the children under 5 had 
elevated functional Ov-103 or Ov-RAL-2 antigen-specific IgE 
responses, while 3/27 and 1/27 of the children 6–8 years of 
age had functional Ov-103 or Ov-RAL-2 antigen-specific IgE 
responses, respectively. Thus, continuous exposure to infective 
larvae with native Ov-103 and/or Ov-RAL-2 proteins did not 
elicit functional IgE in children under the age of 5 living in 
endemic regions in Ghana (Figure 3). This observation is pro-
mising and reduces the concern that these vaccine antigens 
would generate pathological atopic responses in vaccinated 
children (once proven to be safe in adults) as was seen with 
other helminth vaccines when tested in humans [111].
5.2. The candidate vaccine antigens also protect against 
other filarial worms
It is acknowledged that a significant limitation of the 
O. volvulus-mouse model is that the infection was restricted 
to diffusion chambers and that the length of the infection was 
limited to early larval stages. To validate the potency of the 
Ov-103 and Ov-RAL-2 vaccine, the efficacy of Brugia malayi 
orthologous antigens were tested in a B. malayi-gerbil model, 
where the full lifecycle of the parasite develops [106]. Gerbils 
were vaccinated with alum-adjuvanted Bm-103 and Bm-RAL-2 
either individually, co-administered, or as a fusion protein of 
the two antigens. All three vaccine formulations induced pro-
tective immunity measured up to 150 days post-infection. The 
fusion protein or the co-administered vaccines induced more 
consistent and enhanced levels of protective immunity in 
gerbils to B. malayi infection with L3 as compared to levels 
achieved with the individual vaccines. Notably, the vaccines 
promoted reduced fecundity in female worms recovered from 
gerbils vaccinated with the fusion protein or with the co- 
administered vaccines, similar to what was observed in calves 
vaccinated with eight vaccines and exposed to fully developed 
O. ochengi patent infection [95]. Finally, serum from gerbils 
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vaccinated with the individual antigens, or with both antigens 
either co-administered or as a fusion protein, killed L3 in vitro 
in collaboration with peritoneal exudate cells [106]. 
Collectively the studies with B. malayi demonstrated that the 
two antigens induced protective immunity that was enhanced 
by immunization with both vaccine antigens and functioned 
through an antibody/cell-dependent mechanism.
5.3. Effect of host genetics on the efficacy of the 
Ov-103 and Ov-RAL-2 Onchocerca vaccine in mice
Experiments in the mouse-diffusion chamber model utilized 
a limited number of inbred mouse strains and it was ques-
tioned whether the vaccine would be effective in other 
genetic backgrounds. The ability of the vaccine to function 
in a wide variety of genetic backgrounds was considered to be 
critical as the vaccine is intended for use in genetically diverse 
human populations. The efficacy of the O. volvulus vaccine, 
composed of the two antigens Ov-103 and Ov-RAL-2 in com-
bination with the adjuvant Advax-2, was tested in mice with 
disparate genetic backgrounds. Collaborative Cross recombi-
nant inbred strains were crossed resulting in F1 hybrid CC 
Recombinant Inbred Intercross mice (CC-RIX). The resulting 
CC-RIX lines have increased genetic diversity yet are still 
homogenous and reproducible. The O. volvulus vaccine suc-
cessfully induced protective immunity in male and female 
mice in 7 of 8 CC-RIX lines and in BALB/cByJ mice, suggesting 
that this vaccine can induce protective immunity across a wide 
array of genetic backgrounds. Innate protective immunity was 
observed in a single CC-RIX line; however, vaccination of this 
line did not enhance adaptive protective immunity following 
vaccination. Comprehensive analysis of effector cell recruit-
ment, cytokines, chemokines and antibody responses revealed 
that each line of CC-RIX mice had a different adaptive immune 
response profile following vaccination and L3 challenge that 
consisted of a unique combination of multiple immune fac-
tors. Statistical analyses did not reveal correlations between 
individual factors or groups of factors and the presence of 
protective immunity. Studies in the CC-RIX mice demonstrated 
that the bivalent co-administered vaccine composed of Advax- 
2-adjuvanted Ov-103 and Ov-RAL-2 was effective across a wide 
range of genetic backgrounds and suggests that the vaccine 
can induce several different types of protective immune 
mechanisms [113].
6. Clinical development of the onchocerciasis 
vaccine for humans
6.1. Novel lead candidate vaccine antigen construction
Following selection of Ov-103 and Ov-RAL-2 as the lead vac-
cine candidates, we combined them into a single fusion pro-
tein. This is commonly done for subunit vaccines and greatly 
simplifies process development, toxicology, and cGMP manu-
facturing resulting in significant time- and cost-savings. Two 
fusion proteins were generated and tested, Ov-Fus1 and Ov- 
Fus2. The Ov-103 and Ov-RAL-2 subunits were separated by 
a flexible, 12-amino-acid glycine/serine linker (GS) to promote 
independent folding of each subunit. Ov-Fus1 was designed as 
Ov-103-(GS)-Ov-RAL-2, whereas Ov-Fus2 was in the reverse 
orientation. Both fusions were produced in both E. coli and 
P. pastoris. Yeast expression was chosen due to its multiple 
production advantages including scalability, absence of endo-
toxin by-products, more native folding, and potential post- 
translational modifications. Protection studies in mice com-
pared the two fusion constructs with readouts including vac-
cine-induced IgG/IgG1/IgG2 titers, cytokine production, and 
killing of L3 larvae within the diffusion chambers. Ov-Fus1 
(P. pastoris) emerged as the lead protective fusion protein 
vaccine candidate for future clinical development. Producing 
a single fusion antigen would significantly simplify manufac-
turing, testing, and release of the vaccine antigen as well as 
administration to humans.
6.2. Process development of Ov-Fus1
Once the lead fusion vaccine antigen was selected, we 
initiated translational development of the candidate. Ov-Fus1 
was designed in silico without a 6 × His affinity tag, codon 
optimized for production in P. pastoris, and cloned into the 
Figure 3. Measurement of functional IgE responses in children to the antigens Ov-103 and Ov-RAL-2.
Functional anti-Ov-103 (A) or Ov-RAL-2 (B) antigen-specific IgE responses were tested using antigen-specific ImmunoCap assays on sera from 73 children ages 1–5 and 27 children ages 6–8. 
The responses (kUA/L) per age group are plotted. Cutoff (0.35 kUA/L) for functional positive anti-Ov-103 (A) or Ov-RAL-2 IgE responses are marked by dashed lines. 
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vector pPICZα A. P. pastoris transformants were selected on 
YPD agar supplemented with 100 µg/mL zeocin, and indivi-
dual subclones were screened for expression and secretion of 
the antigen. Lead clone (Ov-Fus1-9 H) with highest levels of 
antigen production was used to construct a research cell bank 
(RCB). Ov-Fus1 was initially produced by fermentation at the 
5 L-scale and then using optimized conditions for up to 
30 L-scale. Following fermentation, the clear supernatant was 
filter sterilized, concentrated, diafiltered (20 mM Tris pH 8.0) 
and the Ov-Fus1 protein purified using two ion-exchange 
chromatography steps performed in tandem; a negative 
pass, designed not to bind Ov-Fus1 while binding and remov-
ing non-target proteins followed by a second positive pass (Q 
Sepharose column) resulting in a purity of Ov-Fus1 of ~90%. 
The Ov-Fus1 was then polished to >98% purity using 
a hydrophobic interaction resin. Yields of Ov-Fus1 (~30 kDa) 
averaged 90 mg per liter with endotoxin levels below 100 EU/ 
mg, which is well below the endotoxin levels allowed per 
injection (0.05 EU/mg) of a vaccine, assuming the onchocer-
ciasis vaccine will be tested at 50 or 100 μg per injection. 
Purified Ov-Fus1 was tested for appearance, purity, sterility, 
endotoxin, and concentration before a Certificate of Testing 
was issued.
6.3. Vaccine trials against natural infection with 
O. ochengi in Cameroon
The Adamawa Region of north Cameroon is a major cattle- 
rearing area characterized by savanna grasslands and river 
systems. Unsurprisingly due to the abundance of host species 
and transmission sites, O. ochengi is endemic to this region, 
making it an ideal location to study the bovine-O. ochengi 
natural transmission model as well as the development of 
vaccine-induced protection against natural infection with 
O. ochengi [86,89,90,95,97].
Studying protective immune responses in cattle against 
O. ochengi is challenging because newly exposed, naive cattle 
are generally not maintained long enough to study acquired 
protective immunity or concomitant immunity; however, 
a few studies were able to characterize some of its aspects. 
Naturally acquired infections are typically long-lived, with 
most cattle continuing to acquire new infections over the 
course of their lifetime similar to what is observed in humans 
[4,87,89]. For instance, infected Cameroonian cattle with an 
initial geometric mean nodule load of ~80 acquired an aver-
age of 17 additional nodules when exposed to natural trans-
mission for two additional years, whereas under 2 nodules on 
average were acquired by uninfected putative immune ani-
mals over the same timeframe [114]. Investigation of the 
bovine immune response following experimental infection 
of immunologically naïve animals with O. ochengi demon-
strated that disease progression was also associated with 
a reduction in lymphoproliferative, parasite-specific IgG2 
and pro-inflammatory cytokine (IL-2, IL-4 and IFN-γ) 
responses. Both naturally acquired and vaccine-induced- 
immunity offered some evidence of the types of immune 
responses required for protective immunity [95]. The hetero-
geneity of these naturally acquired and vaccine induced 
immune responses in cattle as well as the scarcity of bovine 
immunological reagents makes a detailed characterization of 
immunity more challenging. Both Th1 and Th2 responses 
appear to be required for protective immunity against 
O. ochengi which is consistent with the findings from rodent 
models investigating vaccine-induced immunity using Ov- 
103, Ov-RAL-2 individually, co-administered, or as a fusion 
protein [105,108].
Current investigations in cattle are presently aimed at max-
imizing the potential protective effects of a co-administration 
of Ov-103 and Ov-RAL-2 or a Ov-Fus1-based adjuvanted vac-
cine in cattle against natural infection with O. ochengi, with 
the intention of inducing antigen-specific mixed Th1 and Th2 
responses. To this end, a number of adjuvant formulations 
have been trialed using three distinct adjuvants, including 
Rehydragel LV alum, a cattle-specific formulation of Advax-2 
which induced a high degree of immunological protection in 
the experimental mouse O. volvulus model, and a veterinary 
water-in-oil-in-water (w/o/w) emulsion (MontanideTM ISA 
206VG) which has previously been shown to induce protective 
immunity in cattle against the parasitic trematode Fasciola 
hepatica [110,115]. Preliminary immunogenicity studies con-
sisting of a prime immunization followed by two booster 
inoculations (1 month apart) have indicated that immuniza-
tion with the Montanide-adjuvanted vaccine was the most 
successful in inducing Th1/Th2-associated antibody 
responses.
The ability to observe and measure the vaccine induced 
immune responses present in cattle following immunization 
and subsequent natural challenge is central to the relevance 
of ongoing and future bovine vaccine trials. This not only 
gives us a better understanding of which components of the 
vaccine and resulting immune response are important for 
immunological protection, but also a deeper appreciation of 
the types of vaccine-induced immune responses to be 
expected in a heterogenous host population, thereby inform-
ing future human clinical trials. There are a number of well- 
established protocols for the investigation of bovine humoral 
and cellular responses, as well as analytical methods to help 
account for the variable nature of immune responses in phe-
notypically diverse populations [116]. Additionally, recent 
advances in omics-type approaches present opportunities for 
in-depth immunological analysis of clinical samples and ex 
vivo cell cultures, which have not previously been possible 
due to the remote field location of these trials [117]. 
Moreover, epitope-mapping techniques can be used with 
serum collected from vaccinated and putatively immune ani-
mals to identify specific natural- and vaccine-induced epitopes 
displaying a high degree of immunogenicity and associations 
with protective immunity for further research and develop-
ment [118,119].
6.4. Selection of final animal model for verification of 
vaccine efficacy prior to testing in humans
While in many cases antigen selection can be performed using 
appropriate models of a pathogen’s lifecycle, due to the com-
plexity of the innate response triggered by adjuvants one 
must consider species-specific differences in receptor path-
ways – particularly when using combination adjuvants that 
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trigger both inflammatory and Toll-like receptors [120,121]. 
Mice tend to have very potent responses to innate agonists – 
perhaps due to their limited lifespan – which would make it 
beneficial for them to respond strongly to invading patho-
gens, as the risk of developing auto-immunity in a short 
time is low [122]. For this reason, considering higher order 
animal models is key to predictive modeling of an adjuvanted 
immune response in humans. Domesticated animals like cows 
and pigs may be a good choice as the close proximity of herds 
mimic human evolution of tribal and city living and thereby 
exposure to innate agonists. Notably, as outlined above, the 
protective responses in humans against O. volvulus and those 
in cattle against O. ochengi were shown to be similar. Despite 
this, and due mostly to evolutionary similarities, non-human 
primates (NHPs) are still considered among the best animal 
models for selecting the best adjuvanted vaccines for humans 
[123]. Other than their innate systems’ similarity, the fact that 
some NHP species are natural hosts for other helminths and 
therefore suffer from diseases like schistosomiasis make them 
excellent models of vaccine efficacy and protection across 
helminth species [124,125]. For these reasons, as part of our 
current plans for the clinical development of the Ov-Fus1 
vaccine for onchocerciasis, we plan to verify protection data 
gathered in mice in NHPs prior to incurring the financial and 
time costs of human clinical development of an imperfect 
vaccine. Current design of our NHP studies includes various 
‘GO/NO GO’ criteria. Among the ‘GO’ criteria would be induc-
tion of neutralizing IgG titers, demonstration of ADCC killing of 
L3 larvae (either in vivo or ex vivo), and induction of cytokines 
indicative of a robust Th1 response. Key ‘NO GO’ criteria will 
likely be failure to kill L3 larvae or reduce parasite burden or 
the induction of IgE antibodies.
6.5. Clinical trial criteria
A clinical path to successful deployment of an onchocerciasis 
vaccine has to take into consideration ‘need, availability and 
cost’ [126]. This breaks down into numerous factors that must 
be considered: The desired indication, the final target popula-
tion, deployment conditions of the product, route of adminis-
tration, and duration of the protective response. It is therefore 
imperative to develop a target product profile prior to enter-
ing clinical trials so that at the end of the human studies the 
data gathered will support the targeted deployment scenario. 
TOVA’s present target product profile for an onchocerciasis 
vaccine in Africa assumes a > 50% efficacy at preventing 
establishment of incoming infections [35]. The target popula-
tion are children under 5 years of age. For these reasons, the 
human clinical trials will be broken down into first testing the 
safety of the vaccine in a non-endemic area, i.e. a phase 1 
human trial in adults to simply demonstrate safety of the 
vaccine formulation in individuals who have not been exposed 
to O. volvulus. Once this is complete, the clinical trial will be 
performed as a phase 1B safety study in endemic countries to 
demonstrate safety and immunogenicity in adult individuals 
who may have encountered the parasite in their lifetime. With 
this in mind, our clinical trial plan will begin by screening 
naïve patient sera for cross-reactivity to Ov-Fus1 alone or to 
total O. volvulus lysates. Post-vaccinated sera will include 
evaluating vaccine-specific responses, IgG titers and cytokine 
induction specific to Ov-Fus1 and again compared to total 
O. volvulus lysates. Future studies would include phase 2 in 
adults where immunological markers of efficacy would be also 
collected (e.g. larvae-specific seroconversion as well as in vitro 
L3 inhibition of molting and/or killing by sera of vaccinated 
individuals in the presence of effector cells), as well as con-
comitant age de-escalation studies to reach the target dosing 
ages. The development of biomarkers for the early diagnosis 
of O. volvulus infections will be an important adjunct during 
this phase [127]. Finally, a pivotal phase 3 efficacy study would 
be performed in children examining prophylactic power of the 
vaccine for registration of the product.
7. Expert opinion
The O. volvulus vaccine composed of two antigens Ov-103 and 
Ov-RAL-2 in combination with the adjuvant alum or Advax-2 
was shown to be consistently effective at inducing protective 
immunity and is now the lead vaccine for clinical develop-
ment. The mechanism of protective immunity induced by the 
vaccine in mice was dependent on the development of an IgG 
response. Likewise naturally acquired human antigen-specific 
monospecific antibodies prevented molting in vitro at 
a statistically significant level. B. malayi orthologues of the 
two vaccine antigens also induced antibodies in gerbils that 
killed larvae in vitro and significantly prevented the develop-
ment of adult worms and fecundity in the developed female 
worms. The vaccine is composed of two antigens inoculated 
as a co-administration or as a fusion vaccine. Each antigen can 
induce protective immunity independently or as a synergized 
protective response when combined. Although alum is an 
effective adjuvant in mice with these vaccine antigens, we 
selected Advax-2 as the adjuvant for further analysis as it 
induced both Th1 and Th2 responses similar to that seen in 
immune humans and protected cows. The adjuvanted vac-
cines elicited immune responses that proved to be essential 
for the uniform success of the vaccine in genetically diverse 
mice, where each protected CC-RIX line responded uniquely to 
the vaccine. The absence of an IgE antibody response in 
vaccinated mice and antigen-specific functional IgE responses 
to each of the vaccine antigens in young children suggests 
that the vaccine will be safe and effective in children. 
Although killing of challenge parasites was not absolute in 
the animal model systems, the vaccine still has clinical applic-
ability assuming that it will result in ~50% decrease in worm 
burden as it does in mice leading to decreases in disease and 
transmission. It is also possible that in humans the vaccine- 
induced protective immune response will be more effective 
because the challenge infection doses are much smaller – as 
found in nature – or because the time for the adaptive 
immune response to kill the new infections has been 
extended beyond the limited time in mice. Even in the 
absence of sterilizing immunity, any reduction in the number 
of adult worms that develop and/or cause significant detri-
mental effect on the fecundity of the developed female worms 
will ultimately result in decreased pathology and transmission. 
The current pre-clinical testing of the Onchocerca vaccine 
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comprised of the two lead vaccine antigens in mice, cows, and 
non-human primates will lead us within the next few years to 
the clinical testing of the vaccine in humans.
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